Millennium, Integrated Core Report ~6% Stakes in AN2 Therapeutics

AN2 Therapeutics, Inc. (ANTX) owners filed a Schedule 13G reporting shared beneficial ownership stakes in Common Stock by a group led by Millennium affiliates and Integrated Core Strategies.

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) owners filed a Schedule 13G reporting shared beneficial ownership stakes in Common Stock by a group led by Millennium affiliates and Integrated Core Strategies. The filing lists holdings of 2,237,102 shares (6.3%) for Millennium Management LLC and affiliates and 2,135,044 shares (6.0%) for Integrated Core Strategies (US) LLC.

The percent figures are calculated using 35,647,635 shares outstanding, which the filing ties to the issuer's reported 27,402,024 shares outstanding as of November 3, 2025 plus 8,245,611 shares issued in a private placement closed on or about March 10, 2026. The filing is a joint Schedule 13G with a Joint Filing Agreement dated March 12, 2026.

Insights

Governance Expert

Large institutional holders disclose passive/shared holdings representing single‑digit stakes.

The filing shows shared voting and dispositive power for 2,237,102 shares by Millennium entities and 2,135,044 shares by Integrated Core Strategies, each reported as ~6% of the class using an outstanding base of 35,647,635 shares. These figures reflect ownership through affiliated entities with shared control.

Implications depend on holder intent and voting coordination; the Joint Filing Agreement dated March 12, 2026 formalizes joint reporting. Subsequent filings would clarify any change in status or voting arrangements.

Investor Relations Analyst

Disclosure clarifies ownership math after a March 2026 private placement.

The percent calculations explicitly tie to the sum of 27,402,024 shares as of November 3, 2025 plus 8,245,611 shares issued in a private placement closed on or about March 10, 2026, totaling 35,647,635 shares outstanding. That base underpins the reported 6.0% and 6.3% stakes.

For clarity, future Form 13 filings or amendments would show whether these holdings remain passive or convert to active positions; cash‑flow treatment is not stated in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership percentages do Millennium and Integrated Core report in ANTX?

Millennium affiliates report 2,237,102 shares (6.3%) and Integrated Core reports 2,135,044 shares (6.0%). These percentages use a common outstanding base of 35,647,635 shares described in the filing.

How did the filing calculate the 35,647,635 shares outstanding for ANTX?

The filing sums 27,402,024 shares as of November 3, 2025 and 8,245,611 shares issued in a private placement closed on or about March 10, 2026. That total equals 35,647,635 shares.

Does the Schedule 13G indicate active control or passive ownership for ANTX holdings?

The filing reports shared voting and dispositive power through affiliated entities and a Joint Filing Agreement dated March 12, 2026. It does not characterize the holdings as active versus passive in the excerpt.

Who signed the joint Schedule 13G for ANTX?

The filing is signed by Gil Raviv, Global General Counsel for the entities and by Israel A. Englander on March 12, 2026, and includes a Joint Filing Agreement as Exhibit I.

Are the shares held directly by Millennium and Integrated Core?

The filing states shares are held by entities subject to voting control and investment discretion by Millennium affiliates; it cautions this should not be construed alone as an admission of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 05:02 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AN2 Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

037326105

(CUSIP Number)

03/06/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 037326105

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,135,044.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,135,044.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,135,044.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 037326105

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,237,102.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,237,102.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,237,102.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 037326105

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,237,102.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,237,102.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,237,102.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 037326105

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,237,102.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,237,102.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,237,102.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AN2 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1300 El Camino Real, Suite 100, Menlo Park, California 94025
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 037326105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page. The percent of class was calculated based on 35,647,635 shares of Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported in the issuer's Form 10-Q filed with the SEC on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued in connection with a private placement that closed on or about March 10, 2026, as reported in the issuer's Form 8-K filed with the SEC on March 10, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	03/12/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	03/12/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	03/12/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	03/12/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of March 12, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.